The targeted cancer drug Ensartinib hydrochloride, developed in China, has become available for purchase nationwide, according to BetPharma, which developed the drug, Xinhua reported on December 17.
The first institution to prescribe the new drug was the Cancer Center at the Sun Yatsen Institute in Guangzhou. Lung cancer is the leading cause of death and the most common malignant neoplastic disease in the country.
Of the total number of cases, 80 to 85% are non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase, one of the main carcinogenic factors of NSCLC, can be activated by genetic lesions in a certain percentage of patients with NSCLC.
Previously, NSCLC patients in China had to rely on imported inhibitors. Ensartinib hydrochloride, as a new generation of powerful inhibitor, represents an important advance in the development of anticancer drugs in China, said Sun Yan, a member of the Chinese Academy of Engineering.
At the end of 2018, the drug was presented for market use in China, and the drug was officially approved for sale on November 19, 2020.
In recent years, the Chinese government has committed itself to speeding up the registration and approval of new anti-cancer drugs, both domestic and foreign, and to develop domestic anti-cancer drugs to replace expensive imported drugs that are urgently needed in clinical practice.